317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
The Readout Loud
00:00
Navigating Pharmaceutical Acquisitions
This chapter examines Recursion's acquisition of Accentia, delving into the challenges and industry dynamics that influence such decisions. It contrasts the performances of leading pharmaceutical companies, particularly focusing on the competitive rivalry between Eli Lilly and Novo Nordisk in the evolving landscape of drug development.
Transcript
Play full episode
